Top New York hospital adopts Inspira (NASDAQ: IINN) ART100 system

(Neutral)

Form Type

6-K

Rhea-AI Filing Summary

Inspira Technologies is expanding its U.S. presence by deploying its FDA-cleared INSPIRA™ ART100 system at a new premier New York academic medical center ranked among the state’s top 10 hospitals. The system is being integrated into the hospital’s clinical workflow for a structured commercial evaluation.

The evaluation aims to define clinical protocols and assess potential broader institutional adoption, adding to existing commercial activity at other leading U.S. healthcare facilities. Inspira positions the ART100 as a foundation for its next-generation ART500 awake-oxygenation system and is also advancing its HYLA™ continuous blood monitoring platform.

FAQ

What did Inspira Technologies (IINN) announce in this 6-K update?

Inspira Technologies announced deployment of its FDA-cleared INSPIRA ART100 system at a new top-tier New York academic medical center. The system will undergo a structured commercial evaluation, expanding Inspira’s footprint in leading U.S. hospitals and supporting potential broader institutional adoption.

What is the INSPIRA ART100 system used for at Inspira Technologies (IINN)?

The INSPIRA ART100 system is FDA-cleared in the U.S. for cardiopulmonary bypass procedures and used for ECMO outside the U.S. It serves as a platform for Inspira’s next-generation ART500, which is designed to provide oxygenation while patients remain awake and breathing spontaneously.

Why is the new New York hospital deployment important for Inspira Technologies (IINN)?

The deployment places the ART100 in a premier academic medical center ranked among New York’s top 10 hospitals. It broadens Inspira’s access to a large patient population and supports its strategy of engaging Tier-1 U.S. institutions for high-profile evaluations and potential long-term adoption.

How will the New York hospital evaluate Inspira Technologies’ ART100 system?

The hospital has integrated the ART100 into its clinical workflow to run a structured commercial evaluation. This process is designed to define clinical protocols and assess whether the system’s performance and workflow fit justify broader institutional adoption within the health system.

What other products is Inspira Technologies (IINN) developing besides the ART100?

Inspira Technologies is developing the INSPIRA ART500, a next-generation system intended to deliver oxygenation while patients remain awake and breathing on their own. The company is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive blood monitoring capabilities.

How does this update fit Inspira Technologies’ U.S. commercial strategy?

The deployment supports Inspira’s U.S. commercial strategy of placing the ART100 in Tier-1 hospitals for structured evaluations. Management highlights a focus on converting these high-profile trials into a sustainable commercial pipeline and further expanding the company’s footprint across key U.S. markets.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 02/18/2026 - 08:31 AM

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of February 2026 (Report No. 6)

Commission File Number: 001-40303

Inspira Technologies Oxy B.H.N. Ltd.

(Translation of registrant’s name into English)

2 Ha-Tidhar St.

Ra’anana 4366504, Israel

(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

☒ Form 20-F ☐ Form 40-F

CONTENTS

On February 18, 2026, Inspira Technologies Oxy B.H.N. Ltd. (the “Company”) issued a press release titled “Inspira Expands U.S. Commercial Footprint: Deploys ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State,” a copy of which is furnished as Exhibit 99.1 with this report of foreign private issuer on Form 6-K.

The first three paragraphs of the press release attached hereto as Exhibit 99.1 are incorporated by reference into the Company’s Registration Statements on Form F-3 (Registration Nos. 333-284308 and 333-289324) and Form S-8 (Registration Nos. 333-259057, 333-277980, 333-285565, 333-290162 and 333-292592), filed with the Securities and Exchange Commission, to be a part thereof from the date on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.

Exhibit No.
99.1		Press Release issued by Inspira Technologies Oxy B.H.N. Ltd. on February 18, 2026, titled “Inspira Expands U.S. Commercial Footprint: Deploys ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State.”

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	Inspira Technologies Oxy B.H.N. Ltd.

Date: February 18, 2026	By:	/s/ Dagi Ben-Noon
		Name:	Dagi Ben-Noon
		Title:	Chief Executive Officer

Exhibit 99.1

Inspira Expands U.S. Commercial Footprint: Deploys ART100 at a New Premier New York Academic Medical Center, Ranked Top 10 in New York State

Ra’anana, Israel, February 17, 2026 – Inspira™ Technologies OXY B.H.N. Ltd. (NASDAQ: IINN, IINNW) (“Inspira Technologies” or the “Company”), a pioneer in innovative life-support and diagnostic technologies, today announced the deployment and initiation of a structured commercial evaluation of its U.S. Food and Drug Administration (“FDA”)-cleared INSPIRA™ ART100 system (the “ART100”) at a new and additional leading U.S. academic medical center.

The partnering institution is a prominent health system serving a large patient population, and is ranked among New York State’s top 10 hospitals in Newsweek’s World’s Best Hospitals 2025 ranking.

This deployment expands Inspira Technologies’ presence within the Tier-1 U.S. hospital market. The ART100 system has been integrated into the center’s clinical workflow to support a structured evaluation designed to define clinical protocols and potential broader institutional adoption. This activity builds upon the Company’s FDA clearance and ongoing commercial activity at other leading U.S. healthcare facilities.

Mike Hershkovitz, Global VP Sales at Inspira Technologies, commented: “This deployment represents a continued execution of our U.S. commercial strategy. Following our recent interaction with other leading healthcare providers, entering another leading institution in New York State demonstrates that the ART100 meets the operational and clinical demands of top-tier U.S. healthcare providers. Our focus remains on converting these high-profile evaluations into a sustainable commercial pipeline and further expanding our footprint across key U.S. markets.”

About Inspira Technologies

Inspira Technologies is a commercial-stage medical device company specializing in advanced respiratory support and real-time blood monitoring solutions. The Company’s FDA-cleared INSPIRA™ ART100 system is approved for cardiopulmonary bypass in the U.S. and ECMO (Extracorporeal Membrane Oxygenation) procedures outside the U.S and serves as a foundation for the development of the INSPIRA ART500, a next-generation system designed to deliver oxygenation while patients remain awake and spontaneously breathing. Inspira Technologies is also advancing HYLA™, a proprietary blood sensor platform offering continuous, non-invasive monitoring. With multiple cleared products, a growing IP portfolio, and strategic streamlining of its operations, Inspira Technologies is increasingly positioned as an attractive platform within the life-support and MedTech landscape. For more information, visit: https://inspira-technologies.com.

Forward-Looking Statements

This press release contains express or implied forward-looking statements pursuant to U.S. federal securities laws. These forward-looking statements are based on the current expectations of the management of the Company only and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. For example, the Company is using forward-looking statements when it discusses that this evaluation builds upon the Company’s FDA clearance and ongoing commercial activity at other leading U.S. healthcare facilities, its U.S. commercial strategy, benefits and advantages of ART100 and conversion of high-profile evaluations into a sustainable commercial pipeline and further expansion of its footprint across key U.S. markets . These forward-looking statements and their implications are based solely on the current expectations of the Company's management and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. Except as otherwise required by law, the Company undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. More detailed information about the risks and uncertainties affecting the Company is contained under the heading “Risk Factors” in the Company's annual report on Form 20-F for the fiscal year ended December 31, 2024, filed with the U.S. Securities and Exchange Commission (the “SEC”), which is available on the SEC's website at www.sec.gov.

Company Contact
Inspira Technologies
Email: info@inspirao2.com
Phone: +972-9-9664485

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

2 documents